activin-receptor-type-1-activin-receptor-like-kinase-2-or-serine2Fthreonine-protein-kinase-receptor-r1-or-tgf-b-superfamily-receptor-type-i-or-alk2-or-acvr1-or-ec-271130---pipeline-review-h2-2016-24marketreports
This report provided by 24 market reports is about,, ‘Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics.
This report provided by 24 market reports is about,, ‘Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
M<strong>ec</strong>hanism Of Action 21<br />
R&D Progress 21<br />
Small Mol<strong>ec</strong>ule 1 To Inhibit ALK2 f<strong>or</strong> Fibrodysplasia Ossificans Progressiva - Drug Profile 22<br />
Product Description 22<br />
M<strong>ec</strong>hanism Of Action 22<br />
R&D Progress 22<br />
Small Mol<strong>ec</strong>ule 2 To Inhibit ALK2 f<strong>or</strong> Fibrodysplasia Ossificans Progressiva - Drug Profile 23<br />
Product Description 23<br />
M<strong>ec</strong>hanism Of Action 23<br />
R&D Progress 23<br />
Synthetic Peptides to Antagonize TGF-Beta R<strong>ec</strong>ept<strong>or</strong> f<strong>or</strong> Diabetic Foot Ulcers, Pulmonary<br />
Fibrosis and Dermatology - Drug Profile 24<br />
Product Description 24<br />
M<strong>ec</strong>hanism Of Action 24<br />
R&D Progress 24<br />
TP-0184 - Drug Profile 26<br />
Product Description 26<br />
M<strong>ec</strong>hanism Of Action 26<br />
R&D Progress 26<br />
TP-0413 - Drug Profile 27<br />
Product Description 27<br />
M<strong>ec</strong>hanism Of Action 27<br />
R&D Progress 27<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
D<strong>or</strong>mant Proj<strong>ec</strong>ts 28<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Featured News & Press Releases 29<br />
D<strong>ec</strong> 07, 2015: Tolero Pharmaceuticals Presents Positive Pr<strong>ec</strong>linical Data on Hepcidin Inhibition<br />
f<strong>or</strong> the Treatment of Anemia Associated with Chronic Disease 29<br />
Nov 12, 2015: Tolero Pharmaceuticals Presents Positive Clinical and Pr<strong>ec</strong>linical Data on<br />
TP-0184 in Leukemia and Anemia at the 57th ASH Annual Meeting and Exposition 29<br />
Aug 18, 2015: La Jolla Pharmaceutical Company R<strong>ec</strong>eives Orphan Drug Designation f<strong>or</strong> Two<br />
Novel Compounds f<strong>or</strong> Fibrodysplasia Ossificans Progressiva 30<br />
Jun 16, 2015: Tolero Pharmaceuticals Presents Positive Pr<strong>ec</strong>linical Data on Hepcidin Inhibition<br />
f<strong>or</strong> the Treatment of Anemia Associated with Chronic Disease 30<br />
Jun 04, 2015: Tolero Pharmaceuticals to Present Pr<strong>ec</strong>linical Pipeline Data On TP-0184 at the<br />
20th Congress of European Hematology Association, EHA 31<br />
Apr 18, 2013: La Jolla Pharma R<strong>ec</strong>eives Orphan Designation From FDA F<strong>or</strong> LJPC-6417 31<br />
Sep 14, 2012: Tolero Pharma R<strong>ec</strong>eives Small Business Innovation Research Contract From<br />
National Cancer Institute 32<br />
Nov 16, 2011: H<strong>or</strong>mone That Controls Iron Levels May Be Target f<strong>or</strong> Atherosclerosis<br />
Treatment 32<br />
Appendix 34<br />
Methodology 34<br />
24marketrep<strong>or</strong>ts | International +1 646 781 7170 | www.24marketrep<strong>or</strong>ts.com
Change language